Research Article

β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease

See allHide authors and affiliations

Science  01 Sep 2017:
Vol. 357, Issue 6354, pp. 891-898
DOI: 10.1126/science.aaf3934

Elucidating the risk of Parkinson's disease

High expression of the α-synuclein gene (SNCA) is a risk factor for Parkinson's disease (PD), but certain drugs may mitigate this risk. Mittal et al. ran a small-molecule screen to identify compounds that regulate levels of SNCA expression and found that several β2-adrenoreceptor (β2AR) agonists reduced them (see the Perspective by Snyder). These compounds modulated epigenetic marks at the SNCA gene, effectively suppressing SNCA transcription. The authors looked at the pharmaceutical history of more than 4 million Norwegians over an 11-year period and found a reduced risk of PD among those that were taking one of the β2AR agonists for other medical problems.

Science, this issue p. 891; see also p. 869

View Full Text

Stay Connected to Science